197 related articles for article (PubMed ID: 21569709)
41. Quantitative analyses of DAPK1 methylation in AML and MDS.
Claus R; Hackanson B; Poetsch AR; Zucknick M; Sonnet M; Blagitko-Dorfs N; Hiller J; Wilop S; Brümmendorf TH; Galm O; Platzbecker U; Byrd JC; Döhner K; Döhner H; Lübbert M; Plass C
Int J Cancer; 2012 Jul; 131(2):E138-42. PubMed ID: 21918973
[TBL] [Abstract][Full Text] [Related]
42. Epigenetic changes in FOXO3 and CHEK2 genes and their correlation with clinicopathological findings in myelodysplastic syndromes.
Sharifi MJ; Zaker F; Nasiri N; Yaghmaie M
Hematol Oncol Stem Cell Ther; 2020 Dec; 13(4):214-219. PubMed ID: 32217071
[TBL] [Abstract][Full Text] [Related]
43. Azacytidine inhibits the proliferation of human promyelocytic leukemia cells (HL60) by demethylation of MGMT, DAPK and p16 genes.
Su Y; Xu H; Xu Y; Yu J; Xian Y; Luo Q
Hematology; 2012 Jan; 17(1):41-6. PubMed ID: 22549447
[TBL] [Abstract][Full Text] [Related]
44. Influence of IL17A polymorphisms on the aberrant methylation of DAPK and CDH1 in non-cancerous gastric mucosa.
Arisawa T; Tahara T; Tsutsumi M; Shibata T
BMC Med Genet; 2012 Jul; 13():59. PubMed ID: 22827846
[TBL] [Abstract][Full Text] [Related]
45. Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia.
Christiansen DH; Andersen MK; Pedersen-Bjergaard J
Leukemia; 2003 Sep; 17(9):1813-9. PubMed ID: 12970781
[TBL] [Abstract][Full Text] [Related]
46. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment.
Daskalakis M; Nguyen TT; Nguyen C; Guldberg P; Köhler G; Wijermans P; Jones PA; Lübbert M
Blood; 2002 Oct; 100(8):2957-64. PubMed ID: 12351408
[TBL] [Abstract][Full Text] [Related]
47. Aberrant methylation in pediatric myelodysplastic syndrome.
Vidal DO; Paixão VA; Brait M; Souto EX; Caballero OL; Lopes LF; Vettore AL
Leuk Res; 2007 Feb; 31(2):175-81. PubMed ID: 16890288
[TBL] [Abstract][Full Text] [Related]
48. Positive correlation of tissue inhibitor of metalloproteinase-3 and death-associated protein kinase hypermethylation in head and neck squamous cell carcinoma.
Nayak CS; Carvalho AL; Jeronimo C; Henrique R; Kim MM; Hoque MO; Chang S; Jiang WW; Koch W; Westra W; Sidransky D; Califano J
Laryngoscope; 2007 Aug; 117(8):1376-80. PubMed ID: 17592394
[TBL] [Abstract][Full Text] [Related]
49. p15INK4b methylation correlates with thrombocytopenia, blast percentage, and survival in myelodysplastic syndromes in a dose dependent manner: quantitation using pyrosequencing study.
Kim M; Oh B; Kim SY; Park HK; Hwang SM; Kim TY; She CJ; Yang I; Yoon SS; Yoon JH; Lee DS
Leuk Res; 2010 Jun; 34(6):718-22. PubMed ID: 19782398
[TBL] [Abstract][Full Text] [Related]
50. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients.
Chan MW; Chan LW; Tang NL; Tong JH; Lo KW; Lee TL; Cheung HY; Wong WS; Chan PS; Lai FM; To KF
Clin Cancer Res; 2002 Feb; 8(2):464-70. PubMed ID: 11839665
[TBL] [Abstract][Full Text] [Related]
51. Aberrant promoter methylation of Dab2 gene in myelodysplastic syndrome.
Yang Y; Zhang Q; Xu F; Chang C; Li X
Eur J Haematol; 2012 Dec; 89(6):469-77. PubMed ID: 23005040
[TBL] [Abstract][Full Text] [Related]
52. Epigenetic therapy in myelodysplastic syndromes.
Musolino C; Sant'antonio E; Penna G; Alonci A; Russo S; Granata A; Allegra A
Eur J Haematol; 2010 Jun; 84(6):463-73. PubMed ID: 20192987
[TBL] [Abstract][Full Text] [Related]
53. Promoter hypermethylation profile of kidney cancer with new proapoptotic p53 target genes and clinical implications.
Christoph F; Weikert S; Kempkensteffen C; Krause H; Schostak M; Köllermann J; Miller K; Schrader M
Clin Cancer Res; 2006 Sep; 12(17):5040-6. PubMed ID: 16951219
[TBL] [Abstract][Full Text] [Related]
54. Promoter hypermethylation analysis in myelodysplastic syndromes: diagnostic & prognostic implication.
Solomon PR; Munirajan AK; Tsuchida N; Muthukumarasamy K; Rathinavel A; Selvam GS; Shanmugam G
Indian J Med Res; 2008 Jan; 127(1):52-7. PubMed ID: 18316853
[TBL] [Abstract][Full Text] [Related]
55. Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome.
Narayan G; Arias-Pulido H; Koul S; Vargas H; Zhang FF; Villella J; Schneider A; Terry MB; Mansukhani M; Murty VV
Mol Cancer; 2003 May; 2():24. PubMed ID: 12773202
[TBL] [Abstract][Full Text] [Related]
56. DNA methylation profiling of myelodysplastic syndrome hematopoietic progenitor cells during in vitro lineage-specific differentiation.
Hopfer O; Komor M; Koehler IS; Schulze M; Hoelzer D; Thiel E; Hofmann WK
Exp Hematol; 2007 May; 35(5):712-23. PubMed ID: 17577921
[TBL] [Abstract][Full Text] [Related]
57. CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine.
Raj K; John A; Ho A; Chronis C; Khan S; Samuel J; Pomplun S; Thomas NS; Mufti GJ
Leukemia; 2007 Sep; 21(9):1937-44. PubMed ID: 17611569
[TBL] [Abstract][Full Text] [Related]
58. Downregulation of HO-1 promoted apoptosis induced by decitabine via increasing p15INK4B promoter demethylation in myelodysplastic syndrome.
Ma D; Fang Q; Wang P; Gao R; Sun J; Li Y; Hu XY; Wang JS
Gene Ther; 2015 Apr; 22(4):287-96. PubMed ID: 25652099
[TBL] [Abstract][Full Text] [Related]
59. DNA repair gene expressions are related to bone marrow cellularity in myelodysplastic syndrome.
Ribeiro HL; Maia ARS; de Oliveira RTG; Costa MB; Farias IR; de Paula Borges D; de Sousa JC; Magalhães SMM; Pinheiro RF
J Clin Pathol; 2017 Nov; 70(11):970-980. PubMed ID: 28554891
[TBL] [Abstract][Full Text] [Related]
60. [Study of aberrant p73 promoter methylation in patients with myelodysplastic syndrome].
Zhao YS; Yang R; Gu SC; Guo J; Zhang X; Wu LY; Li X; Chang CK
Zhonghua Xue Ye Xue Za Zhi; 2012 Oct; 33(10):847-51. PubMed ID: 23384909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
